X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (11) 11
humans (10) 10
female (8) 8
male (8) 8
middle aged (7) 7
aged (6) 6
cardiac & cardiovascular systems (6) 6
cholesterol (5) 5
double-blind method (5) 5
cardiovascular diseases - epidemiology (4) 4
density-lipoprotein cholesterol (4) 4
triglycerides (4) 4
abridged index medicus (3) 3
anticholesteremic agents - adverse effects (3) 3
blood-pressure (3) 3
cardiovascular disease (3) 3
cardiovascular diseases - mortality (3) 3
cardiovascular diseases - prevention & control (3) 3
cholesterol, ldl - blood (3) 3
coronary-heart-disease (3) 3
drug therapy, combination (3) 3
europe - epidemiology (3) 3
follow-up studies (3) 3
guidelines (3) 3
human health and pathology (3) 3
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (3) 3
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (3) 3
medicine, general & internal (3) 3
myocardial-infarction (3) 3
prevention (3) 3
risk factors (3) 3
statins (3) 3
therapy (3) 3
acute myocardial-infarction (2) 2
all-cause mortality (2) 2
analysis (2) 2
anticholesteremic agents - therapeutic use (2) 2
apolipoprotein b (2) 2
apolipoprotein c-iii (2) 2
atherosclerosis (2) 2
atorvastatin (2) 2
azetidines - adverse effects (2) 2
azetidines - therapeutic use (2) 2
canada - epidemiology (2) 2
cardiology (2) 2
cardiology and cardiovascular medicine (2) 2
cardiovascular diseases (2) 2
cerebral infarction (2) 2
cholesterol, hdl - blood (2) 2
cholesterol, hdl - drug effects (2) 2
combination lipid therapy (2) 2
coronary artery disease (2) 2
coronary heart disease (2) 2
cross-sectional studies (2) 2
diabetes (2) 2
diabetes mellitus (2) 2
diabetes mellitus, type 2 - complications (2) 2
diabetes mellitus, type 2 - drug therapy (2) 2
dosage and administration (2) 2
drug therapy (2) 2
drugs (2) 2
dysfunction (2) 2
dyslipidaemias (2) 2
dyslipidemias - epidemiology (2) 2
endocrinology & metabolism (2) 2
endothelial function (2) 2
high-density lipoproteins (2) 2
high-dose atorvastatin (2) 2
hypercholesterolemia - drug therapy (2) 2
kaplan-meier estimate (2) 2
life sciences (2) 2
lipids (2) 2
lipoprotein remnants (2) 2
lipoproteins (2) 2
low hdl-cholesterol (2) 2
low-density lipoproteins (2) 2
lowering ldl cholesterol (2) 2
metaanalysis (2) 2
myocardial infarction (2) 2
pharmacology & pharmacy (2) 2
polymorphism, single nucleotide (2) 2
prognosis (2) 2
renin (2) 2
simvastatin (2) 2
stroke (2) 2
total cardiovascular risk (2) 2
treatment outcome (2) 2
treatment, adherence (2) 2
treatment, drugs (2) 2
treatment, lifestyle (2) 2
triglycerides - blood (2) 2
type-2 diabetes-mellitus (2) 2
14 randomized-trials (1) 1
abdominal aortic-aneurysm (1) 1
ace inhibitors (1) 1
ace-inhibition (1) 1
ace-inhibitor (1) 1
acute coronary syndrome (1) 1
acute coronary syndrome - drug therapy (1) 1
acute coronary syndrome/drug therapy; aged; anticholesteremic agents/adverse effects; anticholesteremic agents/therapeutic use; azetidines/adverse effects; azetidines/therapeutic use; cardiovascular diseases/epidemiology; cardiovascular diseases/mortality; cardiovascular diseases/prevention & control; cholesterol, ldl/blood; double-blind method; drug therapy, combination; ezetimibe; female; humans; hydroxymethylglutaryl-coa reductase inhibitors/adverse effects; hydroxymethylglutaryl-coa reductase inhibitors/therapeutic use; kaplan-meier estimate; male; middle aged; simvastatin/therapeutic use; triglycerides/blood (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Liver | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
by Büller, Harry R and Prins, Martin H and Lensin, Anthonie W. A and Decousus, Hervé and Jacobson, Barry F and Minar, Erich and Chlumsky, Jaromir and Verhamme, Peter and Wells, Phil and Agnelli, Giancarlo and Cohen, Alexander and Berkowitz, Scott D and Bounameaux, Henri and Davidson, Bruce L and Misselwitz, Frank and Gallus, Alex S and Raskob, Gary E and Schellong, Sebastian and Segers, Annelise and Berkowitz, Scott and Gallus, Alexander and Lensing, Anthonie W. A and Haskell, Lloyd and Raskob, Gary and Bauersachs, Rupert and van Bellen, Bonno and Boda, Zoltán and Borris, Lars and Brenner, Benjamin and Brighton, Tim and Davidson, Bruce and Decousus, Herve and Eriksson, Henry and Jacobson, Barry and Kakkar, Ajay and Kwong, Yok-Lam and Lee, Lai Heng and Meijer, Karina and van der Meer, Jan and Monreal, Manuel and Piovella, Franco and Sandset, Per Morten and Smith, Mark and Tomkowski, Witold and Wang, Yuqi and Brandjes, Dees and Mac Gillavry, Melvin and Otten, Hans-Martin and Carlsson, Anders and Laporte, Silvy and Schulman, Sam and Gent, Michael and Turpie, Alexander and Martinelli, Ida and Lensing, Anthonie W and Muhlhofer, Eva and Tewes, Miriam and Trajanovic, Mila and Muller, Karin and Kim, Calvin and Gebel, Martin and Benson, Alice and Pap, Akos Ferenc and Goie, Juliette and Horvat-Broecker, Anea and Spadari, Giovanni and Peters-Wulf, Cornelia and Roig, J and Baker, R and Bianchi, A and Blombery, P and Brighton, T and Campbell, P and Carroll, P and Geraghty, R and Chong, B and Ramanathan, S and Archis, C and Coughlin, P and Salem, H and Crispin, P and Dean, M and Soni, R and Denaro, C and Kubler, P and Coghlan, D and Gallus, A and Gan, T. Eng and Tran, H and Coleman, C and Jackson, D and Khalafallah, A and Leahy, M and Leyden, M and Leyden, D and Sturtz, C and McCann, A and Gibbs, H and McRae, S and Richards, B and ... and The EINSTEIN–PE Investigators and EINSTEIN-PE Investigators and EINSTEIN–PE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2012, Volume 367, Issue 23, pp. 2204 - 2213
Patients with type 2 diabetes at high risk for cardiovascular disease who were already taking a renin–angiotensin system blocker were randomly assigned to the... 
GLOMERULAR-FILTRATION-RATE | CHRONIC HEART-FAILURE | MEDICINE, GENERAL & INTERNAL | CONVERTING-ENZYME INHIBITORS | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | DOUBLE-BLIND | CARDIOVASCULAR MORTALITY | FOLLOW-UP | SYSTOLIC DYSFUNCTION | BLOOD-PRESSURE | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Patient Dropouts | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Kidney Diseases - epidemiology | Treatment Failure | Amides - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Hypokalemia | Female | Drug Therapy, Combination | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Fumarates - therapeutic use | Kidney Diseases - prevention & control | Amides - therapeutic use | Fumarates - adverse effects | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Renin - antagonists & inhibitors | Hyperkalemia - chemically induced | Aged | Kidney Diseases - etiology | Diabetes Mellitus, Type 2 - drug therapy | Angiotensin Receptor Antagonists - therapeutic use | Myocardial infarction | Women | Creatinine | Cerebral infarction | End-stage renal disease | Stroke | Heart attacks | Kidneys | Diabetes mellitus | Cardiovascular disease | Coronary artery disease | Hypotension | Hyperkalemia | Renin | Angiotensin | Renal failure | Diabetes | Kidney diseases | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Heart diseases | Kidney transplantation | Index Medicus | Abridged Index Medicus
Journal Article